Saroglitazar Reduced Liver Fat and Fibrosis in Metabolic Dysfunction Associated Steatotic Liver Disease: A Case Report

Rajesh R. Kulkarni *

Raghavendra Clinic, Darbar galli, Belagavi – 590 001, Karnataka, India.

*Author to whom correspondence should be addressed.


Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) is revised nomenclature of Non-alcoholic fatty liver disease (NAFLD) which is very commonly prevalent condition in India. Currently only one drug Saroglitazar is approved for treatment of NAFLD in India. It is a dual peroxisome proliferator-activated receptor (PPAR α/γ) agonist which improves insulin sensitivity and reduce triglyceride along with liver fat and fibrosis in NAFLD cases. In this case study, MASLD patient was prescribed Saroglitazar 4 mg once daily along with existing anti-diabetic and lipid lowering therapy and at 24 weeks; Saroglitazar had shown significant improvement in glycemic, lipid and transient elastography parameters.

Keywords: Liver fat, liver fibrosis, fatty liver disease, metabolic dysfunction

How to Cite

Kulkarni, Rajesh R. 2024. “Saroglitazar Reduced Liver Fat and Fibrosis in Metabolic Dysfunction Associated Steatotic Liver Disease: A Case Report”. Asian Journal of Case Reports in Medicine and Health 7 (1):93-97.


Download data is not yet available.


Shalimar, Elhence A, Bansal B, Gupta H, Anand A, Singh TP, Goel A. Prevalence of non-alcoholic fatty liver disease in India: A Systematic Review and Meta-analysis. J Clin Exp Hepatol. 2022, May-Jun;12(3): 818-829.

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023, Dec;79(6): 1542- 1556.

Alanazi BM. Updates in the epidemiology of fatty liver and its consequences in Saudi Arabia: A review. Journal of Pharmaceutical Research International. 2022;34(46B):39–46. DOI: 10.9734/jpri/2022/v34i46B36387.

Chopra RK, Mahavir Modi, Sneha Tirpude, Kaumudi Devi, Vishnu Gireesh, Abhijeet Lonsane, Aditya Pandya, Vaibhav Wankhede, Suyash Gandhe. Study to identify the prevalence and predictive factors of post COVID lung fibrosis in COVID-19. Journal of Advances in Medicine and Medical Research. 2022; 34(19):125-34. Available:

Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. American Journal of Transplantation. 2004;4(5):686-693.

Rocha ALL, Faria LC, Guimarães TCM, Moreira GV, Cândido AL, Couto CA, Reis FM. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. Journal of Endocrinological Investigation. 2017;40:1279-1288.

Dharmalingam M, Yamasandhi PG. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J Endocrinol Metab. 2018, May-Jun;22(3): 421-428.

Roy A, Tewari B, Giri S, Goenka M. Saroglitazar in non-alcoholic fatty liver disease from bench to bedside: A Comprehensive review and sub-group meta-analysis. Cureus. 2023, Oct 22;15(10):e47493.

Goyal O, Nohria S, Goyal P, Kaur J, Sharma S, Sood A, Chhina RS. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: A prospective, observational, real world study. Sci Rep. 2020, Dec 3;10(1):21117.

Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, Jaiswal A. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc Diabetol. 2019, Jun 17;18(1):80.

Chaudhuri S, Dutta A, Chakraborty SBD. Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience. JGH Open. 2023, Feb 20;7(3): 215-220.

Duseja A, Singh SP, De A, Madan K, Rao PN, Shukla A, Choudhuri G, Saigal S, Shalimar, Arora A, Anand AC, Das A, Kumar A, Eapen CE, Devadas K, Shenoy KT, Panigrahi M, Wadhawan M, Rathi M, Kumar M, Choudhary NS, Saraf N, Nath P, Kar S, Alam S, Shah S, Nijhawan S, Acharya SK, Aggarwal V, Saraswat VA, Chawla YK. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). J Clin Exp Hepatol. 2023, Mar-Apr;13(2):273-302.

Keam SJ. Resmetirom: First Approval. Drugs. 2024, Jun;84(6):729-735. DOI:10.1007/s40265-024-02045-0. Epub 2024 May 21.

Huang X, Ouyang W, Hu Y, Tang B, He Y, Wu H, Yang P, Yin L, Liu Q, Chen K, Deng J, Li X, Li Y. The effects of weight loss and improved metabolic health status on the risk of non-alcoholic fatty liver disease—results from a prospective cohort in China. Front. Nutr. 2023;10:1239996. DOI: 10.3389/fnut.2023.1239996